POPULARITY
19 episodes with Pancreatic Cancer Action Network
4 episodes with Pancreatic Cancer Action Network
3 episodes with Pancreatic Cancer Action Network
5 episodes with Pancreatic Cancer Action Network
3 episodes with Pancreatic Cancer Action Network
2 episodes with Pancreatic Cancer Action Network
3 episodes with Pancreatic Cancer Action Network
3 episodes with Pancreatic Cancer Action Network
2 episodes with Pancreatic Cancer Action Network
EP273 – They Don't Make Them Like They Used ToThis episode has full video on the YouTube channel @HardParking Have you done the “Tesla Challenge"? Chances are, “No”. This is a made up challenge of seeing how many traffic lights you can go without seeing a Tesla. How many Tesla's are on the road in the United States?A man was arrested for vandalizing as many as 6 Tesla's causing over $21,000 in damages but was NOT charged by county attorney Mary Moriarty, yet she did charge a 19 year old first-time offender for allegedly keying a co-workers vehicle (non Tesla) upwards of $7,000 in damages. How disciplined are you on social media when a friend or colleague makes a post you fundamentally disagree with? What is the real deal with the Trump administration threatening to remove Harvard University's “tax-exempt” status? The All-In Podcast covered this discussion and Jhae plays some of the opinions and responds to them in this episode. What is the real deal about the popular phrase “They don't make them like they used to”? How close are we really to seeing the next generation of the Honda / Acura NSX? Main Show Sponsors:Right Honda: https://righthonda.com/Right Toyota: https://www.righttoyota.com/Arcus Foundry: https://arcusfoundry.com/ Autocannon Official Gear: https://shop.autocannon.com/ Contact Hard Parking with Jhae Pfenning: email: HardParkingPodcast@gmail.com Website: www.Hardparking.comPatreon: www.patreon.com/hardparkingpodcast/ Instagram: instagram.com/hardparkingpod/ YouTube: https://youtube.com/@HardParking Links Referenced in this video:Pancreatic Cancer Action Network: https://pancan.org/ Christy and Sandy's crew: https://secure.pancan.org/site/TR/PurpleStride/PurpleStride?fr_id=2948&pg=team&team_id=59253 All-In-Podcast Podcast segment: (at 28 minute mark on All In pod) Trump vs. Harvard: Why the White House is threatening to take Harvard's tax-exempt status awayhttps://podcasts.apple.com/us/podcast/trump-vs-harvard-nvidia-export-controls-how-dei-killed/id1502871393?i=1000704069760 YouTube channel: https://youtu.be/rCrb4TbHRxc?si=RKixQXc4MvhMQPiH Other Links:https://x.com/SawyerMerritt?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor https://www.smithsonianmag.com/smart-news/why-was-1940s-car-discovered-wreck-american-naval-ship-that-sank-during-world-war-ii-180986485/ https://www.autoevolution.com/news/honda-acura-nsx-for-2030-is-already-here-still-with-ice-power-albeit-only-virtually-250081.html https://kstp.com/kstp-news/top-news/hennepin-county-attorney-wont-charge-man-who-caused-20k-in-damage-to-teslas/ https://www.teslarati.com/atty-no-charge-six-time-tesla-vandal-controversy/ NPR Editorial Staff statistics and congress oversight meeting:Jim Jordan and Katherine Maher (CEO of NPR): https://www.youtube.com/watch?v=H-YBKr40feghttps://washingtonstand.com/news/npr-has-zero-republicans-87-democrats-on-editorial-staff-says-senior-editor- https://oversight.house.gov/hearing/anti-american-airwaves-holding-the-heads-of-npr-and-pbs-accountable/ https://www.cnn.com/2025/04/18/us/harvard-university-endowment/index.html https://www.thecrimson.com/article/2022/7/13/faculty-survey-political-leaning https://www.thefire.org/news/columbia-nyu-join-harvard-bottom-2025-college-free-speech-rankings Bob Jones Univ. v. United States, 461 U.S. 574 (1983) https://supreme.justia.com/cases/federal/us/461/574/ Students for Fair Admissions vs Harvard, 600 U.S. 181 (2023)https://www.oyez.org/cases/2022/20-1199
Today's guests are Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss, Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development of advanced and personalized treatments.TPM E45 highlights >Episode 45 links:Anna Berkenblit on LinkedInSudheer Doss on LinkedInPanCANFor access to data through PanCAN's SPARK platform, please visit: PanCAN.org/sparkFor more information, contact PanCAN Patient Services with questions about any type of pancreatic cancer – we are here to help.
John Billingsley, Kitty Swink, Armin Shimerman, Jonathan Frakes, and Juan Carlos Coto join Anthony and Laurie to talk about the upcoming PurpleStride march to raise money and awareness for the Pancreatic Cancer Action Network. They talk about why it’s so important, plus key changes in research and funding over the past year. Then the gang segues into Star Trek, speculating on the state of the franchise, what caused the end of Berman-era Trek, streaming TV and the era of shorter seasons, Star Trek: Starfleet Academy, and Jonathan Frakes’ farting chair.
John Billingsley, Kitty Swink, Armin Shimerman, Jonathan Frakes, and Juan Carlos Coto join Anthony and Laurie to talk about the upcoming PurpleStride march to raise money and awareness for the Pancreatic Cancer Action Network. They talk about why it’s so important, plus key changes in research and funding over the past year. Then the gang segues into Star Trek, speculating on the state of the franchise, what caused the end of Berman-era Trek, streaming TV and the era of shorter seasons, Star Trek: Starfleet Academy, and Jonathan Frakes’ farting chair.
I am joined in this exploration of narcolepsy by Julie Flygare, an internationally recognized patient-perspective leader, and an accomplished advocate, to discuss her patient perspective of the disease as narrated in her award-winning memoir, Wide Wake and Dreaming. Julie has advanced her leadership in the sleep and healthcare space through speaking engagements, publications, earned media, collaborations, and advocacy and awareness initiatives. Our conversation explored Julie's onset of narcolepsy with excessive sleepiness long before she was diagnosed with narcolepsy after she developed cataplexy. She discussed her on-going struggles with the diverse symptoms of the disease, as well as here validating investigations, and indispensable medical treatments. Our conversation also covered what her diagnosis has taught her regarding prioritising time and appreciating the moment. Prior to accepting her current role as President & CEO of Project Sleep, Julie Flygare served as President of Project Sleep's Board of Directors, while also gaining invaluable experience in marketing and philanthropy at the Pancreatic Cancer Action Network and City of Hope. Julie served on the National Institutes of Health's Sleep Disorders Research Advisory Board from 2012 – 2015, and she delivered the TEDx Talk, “What Can You Learn from a Professional Dreamer? on March 22, 2022,
In this episode of Ameritocracy, host Troy Edgar meets with JB Jaso at our L.A. studio. JB, a former US Army veteran, who made the successful transition from military service to a leadership role in the sports industry. From his Long Beach roots, to serving his country and now overseeing security for the Los Angeles Angels, we look into the challenges and rewards of his military service, including his expertise in Army's Special Operations CBRNE (Chemical, Biological, Radiological, Nuclear, and Explosives) unit and how he prepared for post-service life. JB also discusses Major League Baseball stadium security and his unwavering commitment to giving back. He shares his involvement with the Pancreatic Cancer Action Network, a cause close to his heart, and his leadership role in the Orange County affiliate. Get ready for an inspiring conversation about leadership, service, and community. A great follow-up episode is E36: MLB Pro Scouts Brad (SF Giants), Taylor (TX Rangers) Cameron on Identifying & Developing Talent. Two scouts, 4 World Series rings. Scouting top talent is like stepping up to the plate—whether in business or sports, finding that MVP is every leader's toughest play. In this episode, we dive into how to call strikes on character, make clutch calls on potential, and use tech to knock talent discovery out of the park. Ameritocracy™ is produced by Prospect House Media and recorded in studio locations in Los Angeles and Washington D.C.
Anne Grey brings over 25 years of experience in non-profit leadership to her new role, having held prominent positions at organizations such as Vivalon, the Alzheimer's Association, and the Pancreatic Cancer Action Network. At Vivalon, Anne successfully led the organization through a critical period of growth. Under her leadership, Vivalon saw a significant financial turnaround and was recognized as the Best Nonprofit Organization by the Marin Independent Journal. In 2020, Anne was named one of OC Register's Most Influential People, a testament to her leadership and impact in the community.Anne, who maintains residences in both Irvine, CA, and Rancho Mirage, CA, also emphasized the unique advantage her reach and influence in both Orange County and the Inland Empire will bring to the community that Make-A-Wish serves.Anne holds a Bachelor's degree in International Relations from the University of San Diego and an MBA from Pepperdine University. She is actively involved in the community, serving as a member of the Junior League of Orange County, is a Puppy Den Volunteer for Guide Dogs of the Desert, a member of the Salton Sea Triathlon Club, and Coachella Valley Area Panhellenic.In this episode:Meet Anne GreyAnne's transition to Make-A-WishThe impact of a wish on a child's lifeHer mother's influence in shaping her path towards nonprofit workMission and Impact of Make-A-WishFund Raising and Community SupportThe Wish AlumniThe Norris Group originates and services loans in California and Florida under California DRE License 01219911, Florida Mortgage Lender License 1577, and NMLS License 1623669. For more information on hard money lending, go www.thenorrisgroup.com and click the Hard Money tab.Video LinkRadio Show
In this supplemental edition of All Access Star Trek, Anthony and Laurie are joined by Armin Shimerman, Kitty Swink, Jonathan Frakes, and Juan Carlos Coto (Manny Coto's brother) to talk about the Pancreatic Cancer Action Network, the Purple Stride walk on April 27th, the importance of early detection and family support, the improvements in detection and symptoms to watch out for, why there's hope for the future, and the power of Star Trek fans to do good in the world as a group. They also talk Trek, covering topics like Ferengi makeup new and old, the cancellation of Lower Decks, the definition of “filler episodes,” the differences on set between Star Trek in the '80s and '90s vs. now, and more. John Billingsley was going to join the group, but was unable to make it at the last minute. He will be at the Purple Stride walk! If you can, please join Purple Stride, donate to the cause, or both. If you can't, please spread the word via social media and word of mouth. purplestride.org/TeamTrek
In this supplemental edition of All Access Star Trek, Anthony and Laurie are joined by Armin Shimerman, Kitty Swink, Jonathan Frakes, and Juan Carlos Coto (Manny Coto's brother) to talk about the Pancreatic Cancer Action Network, the Purple Stride walk on April 27th, the importance of early detection and family support, the improvements in detection and symptoms to watch out for, why there's hope for the future, and the power of Star Trek fans to do good in the world as a group. They also talk Trek, covering topics like Ferengi makeup new and old, the cancellation of Lower Decks, the definition of “filler episodes,” the differences on set between Star Trek in the '80s and '90s vs. now, and more. John Billingsley was going to join the group, but was unable to make it at the last minute. He will be at the Purple Stride walk! If you can, please join Purple Stride, donate to the cause, or both. If you can't, please spread the word via social media and word of mouth. purplestride.org/TeamTrek
Hosts Adolph Mongo, Vanessa Moss and Allan Lengel talk with Debbie Kolacki, a retired teacher whose husband Ed died about five years ago from pancreatic cancer. Since then she's been involved with the Pancreatic Cancer Action Network and the Michigan PurpleStride walk which raises money for treatment and research. That event is Saturday, April 27 at the Troy Community Center.The hosts also talk about Donald Trump whining about his trial; the Crumbley case and whether the Renaissance Center should be torn down.
Trek Against Pancreatic Cancer - LIVE! We are joined by the "Trek Against Pancreatic Cancer" team of Kitty Swink, Armin Shimerman, John Billingsley, Jonathan Frakes and Juan Carlos Coto. Each of these people has an amazing connection to Star Trek, and has been affected by Pancreatic Cancer. So tonight we join forces again with these good folks to raise money for Pancreatic Cancer Research. All funds donated go to Pancreatic Cancer Action Network (www.pancan.org) Please donate to this good cause here - https://bit.ly/PurpleStridePanCan Even if you are listening to this on a replay - your donation will still be accepted and will still be helpful for cancer studies. For more on our show partners - Tee See Tee (Use Code FSF15) - www.teeseetee.com Monkey Cult Coffee (use code FSF10) - https://monkeycultcoffee.com/ Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact Tim Beisiegels articles - https://couchsoup.com/author/byeseagull For more on our Show - Join our Patreon https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website - https://www.fsfpopcast.com FSF PopCast on Twitter, Instagram, and Threads - @fsfpopcast
Trek Against Pancreatic Cancer - LIVE! We are joined by the "Trek Against Pancreatic Cancer" team of Kitty Swink, Armin Shimerman, John Billingsley, Jonathan Frakes and Juan Carlos Coto. Each of these people has an amazing connection to Star Trek, and has been affected by Pancreatic Cancer. So tonight we join forces again with these good folks to raise money for Pancreatic Cancer Research. All funds donated go to Pancreatic Cancer Action Network (www.pancan.org) Please donate to this good cause here - https://bit.ly/PurpleStridePanCan Even if you are listening to this on a replay - your donation will still be accepted and will still be helpful for cancer studies. For more on our show partners - Tee See Tee (Use Code FSF15) - www.teeseetee.com Monkey Cult Coffee (use code FSF10) - https://monkeycultcoffee.com/ Level Up Sabers https://bit.ly/FSFLevelUpSabers Win free loot - sign up here - www.fsfpopcast.com/contact Tim Beisiegels articles - https://couchsoup.com/author/byeseagull For more on our Show - Join our Patreon https://patreon.com/fsfpopcast Join our Discord! https://discord.gg/cpry4fCDTq Visit our website - https://www.fsfpopcast.com FSF PopCast on Twitter, Instagram, and Threads - @fsfpopcast
Starting April 1, 2024, Diane M. Simeone, MD will start her new position as director of the University of California San Diego (UCSD) Health Moores Cancer Center.1 In a conversation with CancerNetwork®, Simeone highlighted her excitement to be working with an institution that she said aligns with her goals and values. During her time as director, she said that she wants to focus more on early detection of pancreatic cancer, which may help save many patients. Additionally, some of her short- and long-term goals include submitting a Cancer Center Support Grant to the National Institutes of Health and expanding clinical trial efforts at UCSD. She also discussed ongoing projects she will aim to work on, such as the UC Pancreatic Cancer (UCPCC) Consortium and the Pancreatic Cancer Early Detection (PRECEDE) Consortium.2,3 Prior to beginning her new position at UCSD, Simeone has been the Laura and Isaac Perlmutter Professor of Surgery, director of the Pancreatic Cancer Center, and the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. Additionally, she was previously the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and a member of the scientific advisory board for the Let's Win Pancreatic Cancer online community. “It was clear that everybody is aligned with this mission and understands the importance of how we care for patients with cancer and do research at the cancer center,” Simeone said during the interview. “There seems to be a clear commonality of thinking on their vision of being at the forefront of advancing science and, most importantly, how we apply to take care of patients. Patients are always the driving force. That's always the center of what we need to be thinking about.” References 1. World-renowned surgeon named new director of Moores Cancer Center at UC San Diego Health. News release. University of California San Diego. January 8, 2024. Accessed January 25, 2024. http://tinyurl.com/4986f4cb 2. UC Pancreatic Cancer Consortium. University of California Health. Accessed January 25, 2024. http://tinyurl.com/3szdvyxv 3. PanCAN's Precision Promise adaptive clinical trial platform –. Pancreatic Cancer Action Network. Published April 27, 2016. Accessed January 25, 2024. http://tinyurl.com/fpax5hhd
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Margaret Tempero, MD, is an internationally renowned expert in pancreatic cancer, a Professor of Medicine and Director of the Pancreas Center at the UCSF Comprehensive Cancer Center. She organized the first Pancreas Cancer Think Tank in 1999 and chairs The Pancreatic Cancer Action Network's (PanCAN) Scientific and Medical Advisory Board. She was recently inducted into the prestigious Giants of Cancer Care. A thought leader in cancer, she is a former president of the American Society of Clinical Oncology and American Pancreatic Association and currently serves on the ASCO Conquer Cancer Foundation Board. She also serves as the Editor of Chief of Journal of National Comprehensive Cancer Network. “I remember asking a mentor of mine, ‘What does success mean?'” In her mind, Dr. Margaret Tempero expected an obvious answer: Some prestigious designation, a decorated award, maybe some groundbreaking research to her name; but when Dr. Ann Kessinger responded with the most fundamental truth of medicine, it revolutionized her medical philosophy to its core: “You're successful when you're improving the lives of your patients, plain and simple.” Join us for another episode of The Medicine Mentors as Dr. Margaret Tempero shares the true definition of success in medicine, teaches us how to improve the lives of our patients, and emphasizes getting to know the patient as a person before we know them by their disease. Pearls of Wisdom: 1. Success in medicine is found when you're improving the lives of your patients. Regardless of how you do it, the patient must be the first and center focus. 2. Get to know your patient as a person before you know them as a disease. It's as simple as asking them to tell you about themselves. Know the patient so you can help cater your discussion to a field that they understand. 3. Mentorship can be thought of like tennis; a bidirectional process where if your opponent is better, you do better. Mentees have to bring the full initiative to the mentor so they can play back.
Fred Krupp, President of the Environmental Defense Fund, discusses working with leading companies to create a more sustainable world. Julie Fleshman, President and CEO of Pancreatic Cancer Action Network, talks about pancreatic cancer awareness month and "Change The Course” campaign. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.See omnystudio.com/listener for privacy information.
Fred Krupp, President of the Environmental Defense Fund, discusses working with leading companies to create a more sustainable world. Julie Fleshman, President and CEO of Pancreatic Cancer Action Network, talks about pancreatic cancer awareness month and "Change The Course” campaign. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.See omnystudio.com/listener for privacy information.
We're thilled to introduce our sister podcast, The P2P Soap Box with Marcie Maxwell. In the very first episode, Pancreatic Cancer Action Network's CEO Julie Fleshman and Board member Peter Cashion join Marcie to talk about the profound impact of peer-to-peer fundraising and how they champion it from the top-down.—Despite raising over $1 billion in 2022, peer-to-peer fundraising often fails to receive the recognition it deserves in the world of development and even from the top leadership within nonprofit organizations. There is an ever-present notion that "Walks are dead," but these misguided voices fail to comprehend the true power of peer-to-peer fundraising. In fact, peer-to-peer fundraising is the most democratic form of fundraising, empowering individuals directly affected by our mission to come together and raise funds to combat challenges, seek cures, promote accessibility in treatments, and create a better world.It is only when organizational leaders grasp the potential of peer-to-peer fundraising that we can elevate our efforts to unparalleled levels of success.In this inaugural episode, P2PPF's Marcie Maxwell is joined by Julie Fleshman, President & CEO of the Pancreatic Cancer Action Network (PanCAN) and Peter Cashion, Purple Stride team captain and member of the PanCAN Board of Directors. Peter was also the winner of the 2023 Cash, Sweat & Tears Award presented at the 2023 Peer-to-Peer Professional Forum Conference in Washington, DC. Both Julie & Peter share their very personal stories of losing a loved one to pancreatic cancer - and how they have find new purpose in fundraising and a sense of community through PanCAN's signature event, Purple Stride. They also discuss how they are deepening their Board's engagement with peer-to-peer fundraising and the impact that has on their staff and volunteers.In today's episode, we'll explore:How peer-to-peer fundraising can empower a communityHow PanCAN is mobilizing its board to participate in peer-to-peer fundraisingThe decision-making process that went into moving all Purple Stride walks to the same day nationwideMentioned LinksPancreatic Cancer Action NetworkPurple StrideStay Connected on LinkedInConnect with JulieConnect with PeterConnect with MarcieConnect with the Peer-to-Peer Professional Forum (00:00) - Welcome to Engage for Good
Despite raising over $1 billion in 2022, peer-to-peer fundraising often fails to receive the recognition it deserves in the world of development and even from the top leadership within nonprofit organizations. There is an ever-present notion that "Walks are dead," but these misguided voices fail to comprehend the true power of peer-to-peer fundraising. In fact, peer-to-peer fundraising is the most democratic form of fundraising, empowering individuals directly affected by our mission to come together and raise funds to combat challenges, seek cures, promote accessibility in treatments, and create a better world.It is only when organizational leaders grasp the potential of peer-to-peer fundraising that we can elevate our efforts to unparalleled levels of success.In this inaugural episode, P2PPF's Marcie Maxwell is joined by Julie Fleshman, President & CEO of the Pancreatic Cancer Action Network (PanCAN) and Peter Cashion, Purple Stride team captain and member of the PanCAN Board of Directors. Peter was also the winner of the 2023 Cash, Sweat & Tears Award presented at the 2023 Peer-to-Peer Professional Forum Conference in Washington, DC. Both Julie & Peter share their very personal stories of losing a loved one to pancreatic cancer - and how they have find new purpose in fundraising and a sense of community through PanCAN's signature event, Purple Stride. They also discuss how they are deepening their Board's engagement with peer-to-peer fundraising and the impact that has on their staff and volunteers.In today's episode, we'll explore: How peer-to-peer fundraising can empower a community How PanCAN is mobilizing its board to participate in peer-to-peer fundraising The decision-making process that went into moving all Purple Stride walks to the same day nationwide Mentioned LinksPancreatic Cancer Action NetworkPurple StrideStay Connected on LinkedInConnect with JulieConnect with PeterConnect with MarcieConnect with the Peer-to-Peer Professional Forum (00:00) - Welcome to The P2P Soap Box (05:52) - Introducing Jule Fleshman (08:02) - Introducing Peter Cashion (13:22) - Turning passion into service (17:15) - Mobilizing Board Support (22:29) - Strategic Scheduling (30:42) - Get Involved • https://pancan.org
The Professor Is In Armin Shimerman has come back to the FSF PopCast to talk more Trek, more Buffy, and of course his recently released book -"Illyria - Imbalance of Power". We talk to Armin about this book, the 3rd in his Illyria trilogy, the characters within the story and their real life historical influence and prominence to the Shakespearean age of writing. We also talk with Armin about the work that he and his wife Kitty are doing in behalf of the Pancreatic Cancer Action Network or PANCAN. This charity is vitally important to both Kitty and Armin since Kitty is a Pancreatic Cancer survivor. We talk about what's needed now, and how you can help. And we also put some of our listeners questions in front of Armin to see what he would say. For more on Armin Shimerman and his books, please visit the following - arminshimerman.com For more on The Pancreatic Cancer Action Network, please visit the following - pancan.org For RSWOF Merch - https://www.teepublic.com/t-shirt/31938193-rswof?store_id=1397534 100% of all proceeds Benefit Wish Upon a Teen For direct contributions - www.wishuponateen.org Join our Discord! https://discord.gg/cpry4fCDTq FSF PopCast on Twitter and Instagram - @fsfpopcast Buy us Coffee - https://ko-fi.com/fsfpopcast For more on our show partners - Big Boy Graphics - www.etsy.com/shop/bigboygraphics Bridgework Studios - https://www.teepublic.com/user/bridgework-studios Level Up Sabers - https://shareasale.com/r.cfm?b=2018189&u=3289465&m=124959&urllink=&afftrack=
The Professor Is In Armin Shimerman has come back to the FSF PopCast to talk more Trek, more Buffy, and of course his recently released book -"Illyria - Imbalance of Power". We talk to Armin about this book, the 3rd in his Illyria trilogy, the characters within the story and their real life historical influence and prominence to the Shakespearean age of writing. We also talk with Armin about the work that he and his wife Kitty are doing in behalf of the Pancreatic Cancer Action Network or PANCAN. This charity is vitally important to both Kitty and Armin since Kitty is a Pancreatic Cancer survivor. We talk about what's needed now, and how you can help. And we also put some of our listeners questions in front of Armin to see what he would say. For more on Armin Shimerman and his books, please visit the following - arminshimerman.com For more on The Pancreatic Cancer Action Network, please visit the following - pancan.org For RSWOF Merch - https://www.teepublic.com/t-shirt/31938193-rswof?store_id=1397534 100% of all proceeds Benefit Wish Upon a Teen For direct contributions - www.wishuponateen.org Join our Discord! https://discord.gg/cpry4fCDTq FSF PopCast on Twitter and Instagram - @fsfpopcast Buy us Coffee - https://ko-fi.com/fsfpopcast For more on our show partners - Big Boy Graphics - www.etsy.com/shop/bigboygraphics Bridgework Studios - https://www.teepublic.com/user/bridgework-studios Level Up Sabers - https://shareasale.com/r.cfm?b=2018189&u=3289465&m=124959&urllink=&afftrack=
A Vorta and a Bajoran Walk into a Spaceport You may best recognize this week's guest from her work on Babylon 5, Star Trek Deep Space Nine, JAG, NYPD Blue, Becker and more! Kitty Swink is our guest this week, and we are excited to have her join us! Kitty talks about her work in the performing arts over the years, her love for Star Trek and how its impacted her life, her fight with pancreatic cancer and survival along with her work with the Pancreatic Cancer Action Network and more! Be sure to check out her response to WikiData claiming they have proof that she's an actual human! You can find out more about the Pancreatic Cancer Action Network by visiting www.pancan.org For more information about Kitty Swink, please visit the following - Twitter - @kitswink For RSWOF Merch - https://www.teepublic.com/t-shirt/31938193-rswof?store_id=1397534 100% of all proceeds Benefit Wish Upon a Teen For direct contributions - www.wishuponateen.org Join our Discord! https://discord.gg/cpry4fCDTq FSF PopCast on Twitter and Instagram - @fsfpopcast Buy us Coffee - https://ko-fi.com/fsfpopcast For more on our show partners - Big Boy Graphics - www.etsy.com/shop/bigboygraphics Bridgework Studios - https://www.teepublic.com/user/bridgework-studios Level Up Sabers - https://shareasale.com/r.cfm?b=2018189&u=3289465&m=124959&urllink=&afftrack= Support The FSF PopCast by contributing to their tip jar: https://tips.pinecast.com/jar/funny-science-fiction
A Vorta and a Bajoran Walk into a Spaceport You may best recognize this week's guest from her work on Babylon 5, Star Trek Deep Space Nine, JAG, NYPD Blue, Becker and more! Kitty Swink is our guest this week, and we are excited to have her join us! Kitty talks about her work in the performing arts over the years, her love for Star Trek and how its impacted her life, her fight with pancreatic cancer and survival along with her work with the Pancreatic Cancer Action Network and more! Be sure to check out her response to WikiData claiming they have proof that she's an actual human! You can find out more about the Pancreatic Cancer Action Network by visiting www.pancan.org For more information about Kitty Swink, please visit the following - Twitter - @kitswink For RSWOF Merch - https://www.teepublic.com/t-shirt/31938193-rswof?store_id=1397534 100% of all proceeds Benefit Wish Upon a Teen For direct contributions - www.wishuponateen.org Join our Discord! https://discord.gg/cpry4fCDTq FSF PopCast on Twitter and Instagram - @fsfpopcast Buy us Coffee - https://ko-fi.com/fsfpopcast For more on our show partners - Big Boy Graphics - www.etsy.com/shop/bigboygraphics Bridgework Studios - https://www.teepublic.com/user/bridgework-studios Level Up Sabers - https://shareasale.com/r.cfm?b=2018189&u=3289465&m=124959&urllink=&afftrack= Support The FSF PopCast by contributing to their tip jar: https://tips.pinecast.com/jar/funny-science-fiction
GIRL! GET READY TO GO TO CHURCH ON A WEDNESDAY!Jerakah Heady is a podcaster, author, multi-passionate entrepreneur, speaker and self proclaimed Target Shopping Connoisseur on a mission to help ambitious women make themselves a priority.Jerakah is your internet BFF. She keeps it real, raw, honest and graceful.We recorded this back in September before many people knew my dad was sick, and it hit so close to home while we were talking about grief and her book that she is currently working on… But as I was listening back to our chat again this week, it was even MORE powerful for me and I found myself feeling so grateful to have had this conversation when we did and being able to listen to it now when I really need it.***But a quick trigger warning… we talk about infertility and infant loss, so if those are triggering topics for you -1. I want to grab you and squeeze you and tell you I love you and 2. I give you full permission to protect your peace and not continue with this particular episode and I will see you next week! LOVE YOU. MEAN IT.WAYS TO CONNECT WITH JERAKAH ~IG: @jerakahheady20 Gifts of Gratitude Book: https://amzn.to/3ih12tgGrit & Gratitude Podcast: https://apple.co/3ALvMZFWebsite: www.jerakahheady.com**LAST CALL**Please don't forget that we are raising money for Pancreatic Cancer Action Network for earlier detection to save lives! You can shop online at our Bonfire store all month long in November and all proceeds will be donated directly to PanCAN! Head to bonfire.com/store/hope-for-pancreatic-cancer/ to shop many different styles, designs and sizes. As of this recording, we have raised $800! My goal is to hit $1000, so go shopping or share our campaign with othersI THANK YOU for spreading awareness of this horrible disease. WAYS TO HELP OUR PODCAST GROW ~- RATE & REVIEW the podcast so that we can help the algorithm to suggest it to even more Mamas who need to hear it! Once we hit 100 reviews on Apple ITunes, I am giving away $50!WAYS WE CAN CONNECT ~- Come hangout with me on Instagram - https://www.instagram.com/chrystylockhart/- Text STARTSCARED to (855) 849-0997 to subscribe to my FREE Text List!*DISCLAIMER: The information and opinions contained in Start Scared is for personal and entertainment purposes only. I am SO grateful that you're here and to be on this journey WITH you, girl! Cheers to US and our growth together! I love you, I am rooting for you and remember, YOU MATTER.
I am in the HARDEST season of my life, but I am finding myself stopping and sitting in GRATITUDE.I am forever thankful for YOU for allowing me to share this journey.I am forever thankful for those who came to celebrate my dad.I am forever thankful for the amazing stories shared at his celebration.I am forever thankful for my family and friends who have been so strong for us.So. Much. Gratitude.As we enter Thanksgiving, even if you are in your own hard season, I want YOU to find something to be grateful for... Even if it is as small as the birds chirping. There is ALWAYS something to be grateful for.And because you have been here for ALL of my dad's illness, I want you to get to know him better, so THANK YOU for letting me share with you what I shared at his Celebration of Life.**Please don't forget that we are raising money for Pancreatic Cancer Action Network for earlier detection to save lives! You can shop online at our Bonfire store all month long in November and all proceeds will be donated directly to PanCAN! Head to bonfire.com/store/hope-for-pancreatic-cancer/ to shop many different styles, designs and sizes. As of this recording, we have raised $766! My goal is to hit $1000, so go shopping or share our campaign with othersI THANK YOU for spreading awareness of this horrible disease. WAYS TO HELP OUR PODCAST GROW ~- RATE & REVIEW the podcast so that we can help the algorithm to suggest it to even more Mamas who need to hear it! Once we hit 100 reviews on Apple ITunes, I am giving away $50!WAYS WE CAN CONNECT ~- Come hangout with me on Instagram - https://www.instagram.com/chrystylockhart/- Text STARTSCARED to (855) 849-0997 to subscribe to my FREE Text List!*DISCLAIMER: The information and opinions contained in Start Scared is for personal and entertainment purposes only. I am SO grateful that you're here and to be on this journey WITH you, girl! Cheers to US and our growth together! I love you, I am rooting for you and remember, YOU MATTER.
November 17, 2022 is World Pancreatic Cancer Awareness Day and November is Pancreatic Cancer Awareness Month. Julie Fleshman is the president and CEOr of the Pancreatic Cancer Action Network. In this chat, Julie shares life saving information about findings from a recent survey, the common signs and symptoms of pancreatic cancer and how to be your own best advocate to detect pancreatic cancer. (www.PanCAN.org)
My dad, Geoff Leighton, was diagnosed with Pancreatic Cancer in August 2022, and he died peacefully in his sleep on November 6, 2022, with my mom and me by his side... Although we are left to grieve on Earth, I am filled with peace that we will see him again in Heaven.Please don't forget that we are raising money for Pancreatic Cancer Action Network for earlier detection to save lives! You can shop online at our Bonfire store all month long in November, and all proceeds will be donated directly to PanCAN! Head to bonfire.com/store/hope-for-pancreatic-cancer/ to shop many different styles, designs and sizes. THANK YOU for spreading awareness of this horrible disease.And also… Especially If you have Pancreatic Cancer in your family, I highly suggest you ask your doctor to do a blood test for CA 19-9, which is an inexpensive test and should be covered by insurance. A high level of CA 19-9 can often be a sign of pancreatic cancer, so then you can follow up with a CT scan. WAYS TO HELP OUR PODCAST GROW ~- RATE & REVIEW the podcast so that we can help the algorithm to suggest it to even more Mamas who need to hear it! Once we hit 100 reviews on Apple ITunes, I am giving away $50!WAYS WE CAN CONNECT ~- Come hangout with me on Instagram - https://www.instagram.com/chrystylockhart/- Text STARTSCARED to (855) 849-0997 to subscribe to my FREE Text List!*DISCLAIMER: The information and opinions contained in Start Scared is for personal and entertainment purposes only. I am SO grateful that you're here and to be on this journey WITH you, girl! Cheers to US and our growth together! I love you, I am rooting for you and remember, YOU MATTER.
At the time of this recording, my sweet daddy has taken a turn for the worse and instead of bringing you the golden nuggets that I learned from Amber Lilyestrom at the EmpowerHER Live event back in October, I am bringing real and raw and what is on my heart...Girl... don't waste the time you have on this Earth...Stop waiting and start living.Tell the people you love that you love them.Do the things that bring you joy.Take that trip.DON'T WAIT.Because you never know when your time will be up...Edited to add: I recorded this episode less than 5 hours before my sweet daddy went to be with Jesus.
This week I talked to Lisa Gilmour who lost her brother to pancreatic cancer. Before he passed, she promised him she would do everything she could to make a difference. We talk about how his illness impacted their family and what it means to cultivate a sparkle of hope. To learn more about the Pancreatic Cancer Action Network, go to pancan.org/. If you enjoyed this conversation please leave a review in your podcast app. CancerTalks is a platform for anyone who has been touched by cancer. Write to us at info@cancertalks.com if you have a story to share. If you're moved to donate, please visit cancertalks.com/donate.
Customer narratives are a transformative tool to help you build successful products! Marco Argenti (CIO @ Goldman Sachs) explains how to develop these narratives as your team's guiding vision and help eng orgs better understand “the business” side of software. Plus we cover best practices for investing in developer experience, Goldman Sachs' transition to prioritize external developers, and the signs, signals and trends Marco's used to navigate his career across tons of different emerging technology fields.ABOUT MARCO ARGENTIMarco Argenti is the Chief Information Officer at Goldman Sachs. He is a member of the Management Committee, the Firmwide Technology Risk Committee, the Client Business Standards Committee, the Enterprise Risk Committee and the Global Inclusion and Diversity Committee. Mr. Argenti joined the firm as a Partner in 2019.Prior to joining Goldman Sachs, Mr. Argenti served as Vice President of technology of Amazon Web Services (AWS) since 2013, overseeing all aspects of the product lifecycle of Cloud Services, including strategy, business planning and developer engagement, and leading several AWS technology areas, such as mobile, serverless, Internet of Things, messaging, and augmented and virtual reality. Before that, Mr. Argenti spent several years at Nokia Corporation, where he was Senior Vice President and Global Head of Developer Experience and Marketplace from 2011 to 2013, with responsibility for Nokia's developer ecosystem and app store across the company's entire product portfolio.Earlier in his career, Mr. Argenti was a board member and Chief Executive Officer of internet and mobile company Dada S.p.A., as well as a board member, executive vice president of strategy development and chief technology officer of Canadian e-commerce solutions provider Microforum Inc., where he founded Internet Frontier Inc., an internet publisher and e-commerce retailer. He previously founded and sold Dreamware S.r.l., a software development firm, to Microforum Inc.Mr. Argenti serves on the Board of Directors of the Seattle Symphony Orchestra and the Pancreatic Cancer Action Network, also known as PanCan. He is also a member of the Board of Trustees of Carnegie Hall."Today, the world is so complex that it's almost like an asteroid field and when you navigate an asteroid field, if you don't turn often, you're gonna be having some surprises and so that's why iteration is so important. You need to release sometimes multiple times a day because the world is changing in front of you and there are opportunities and obstacles that come all the time."- Marco Argenti Our in-person conference ELC Annual returns 10/27-28!Learn from 60+ of the best engineering leaders in the industry / Critical insights on leadership, career and technology / Plus tons of experiences optimized for deep conversations & meaningful connections - all to help you build your support network!Don't miss out on being part of the biggest celebration of engineering leadership of the year!Grab your ticket HERE: sfelc.com/annual2022SHOW NOTES:Marco's leadership journey – as a CTO, VP of Tech, and beyond (2:39)Questioning biases & observing signals when predicting opportunities (8:41)How Marco used intuition & data when deciding to work with Goldman Sachs (10:10)Why engineers must understand business principles (13:46)Using customer narratives to create a guiding vision for eng teams (17:47)How to help eng orgs better understand the business metrics of software (22:01)Why Goldman Sachs transitioned to prioritizing its developer clients (25:39)Shifting the focus from internal developers to external developers (31:34)How the tech team navigated challenges during this transition (33:34)Rapid fire questions (36:43)
Another Tourney of Champs episode featuring Jeopardy winners Ben Henri vs. Kevin Walsh. These two square off for four rounds of trivia and reminisce about their time with Alex Trebek on Jeopardy. Ben is playing for Pancreatic Cancer Action Network and Kevin is playing for the American Heart Association. Rate, review and subscribe! Follow us @youshouldknowbetterpod
In the first episode of Death, Grief And Other Shit We Don't Discuss, Kyle McMahon tells the story of receiving his mother Joanne's pancreatic cancer diagnosis, how he and his family handled it and how it changed their lives forever.Then, Kyle talks with Dr. Nicole Duffy, a health psychologist at ChristianaCare's Helen F. Graham Cancer Center & Research Institute, about healthy ways to deal with a life-threatening diagnosis. Get resources related to this episode at: RESOURCES: Episode 1: The Diagnosis (aka WTF?!?)
Eleven people out of one hundred will be alive five years after their pancreatic cancer diagnosis. The five-year survival rate for pancreatic cancer patients has increased recently from a single digit number to 11%. Tori Larrick, Patient Services Manager ll with the Pancreatic Cancer Action Network recently shared with us why early detection and better treatment options are some of the reasons why we are seeing this increase. This episode of Living Hope is dedicated to PanCAN's Survivor Council and Survivor Council Alumni. The Survivor Council was formed to represent the voice of survivors and they are committed to ensuring that the survivor perspective is integrated into all that PanCAN does.
I can't believe a year has come and gone! Who knew, for me the first episode I would go from "Executive Producer," to actually becoming the host. Looking back through our first year, so many amazing journeys, each one left me with wanting to learn more. We shared so many emotions, laughter and tears but each one filled with love. Many of the journey's may not have had the outcome we hoped for but we still found something positive, some strength we could take from every journey. Join us on our weekly journey as we provide hope here only on OC Talk Radio Orange County's only radio station live streaming from our station here at UCI Beall Innovation Center at the Cove For Patient Services please contact the Pancreatic Cancer Action Network at 877-PAN 2-CAN Share your journey by contacting us at octalkradio.net or paul@octalkradio.net https://www.facebook.com/LivingHope2055 or email livinghopepc@outlook.com Check out the Hirshberg Foundation for Pancreatic Cancer Research https://pancreatic.org/ for the recording of the 16th Annual Symposium that took place on April 23, 2022
Cycle Squad water bottle - all proceeds will benefit Pancreatic Cancer Action Network: https://www.etsy.com/listing/1208848512/jared-sklar-water-bottle-cycle-squad?click_key=37f32e37d3cf0fc65dae6c670df9b56098c4d31f%3A1208848512&click_sum=e57ea837&ref=shop_home_active_1&sts=1 Follow Jared Sklar https://instagram.com/sklartacus?igshid=YmMyMTA2M2Y= Jared Sklar merch https://thebakeryisopen.myshopify.com/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/emma-olson5/support
Pancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030."So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."
Tori Larrick, Patient Service Manager with the Pancreatic Cancer Action Network guides us through clinical trials, what to expect and why clinical trial participation is safe. Tori encourages anyone considering clinical trials to feel comfortable with reaching out to Patient Services and asking questions. The first step is to feel free to contact PanCAN Patient Services. They're happy to talk through any fears or concerns before making a decision. You can reach out to them on the website pancan.org, call 877-2-PANCAN or email patientservices@pancan.org This episode of Living Hope is dedicated to our Caregivers. Caregivers are important to the Survivor's journey. We thank our Caregivers and want you to know you are not alone, we are here for you. Regardless of where you are as a Caregiver you can reach out and speak with a Patient Service Case Manager and also ask to be connected with another Caregiver to share experiences. Clarification on what is the Institutional Review Board: An IRB consists of at least five members of varying and diverse backgrounds. IRB members should have the professional experience to provide appropriate scientific and ethical review. An IRB must have at least one scientist member and at least one member whose primary concerns are nonscientific.
Tori Larrick, is a Manager ll, Patient Services with the Pancreatic Cancer Action Network. Tori has been with PanCAN for five years and was drawn to the organization due to the loss of her father to pancreatic cancer. Tori supervises a team of Case Managers in the Patient Services department which provides information and resources to patients and families affected by pancreatic cancer. Tori oversees the GenomOncology Explorer and biomarker search process for the Patient Services team and has extensive experience with clinical trials. Tori brings to light the importance of clinical trials for those diagnosed with pancreatic cancer and debunks the myths of clinical trials, here @OC Talk Radio Orange County's only community radio station streaming live from @UCI Beall Applied Innovation at the Cove. “As long as you speak my name I shall live forever.” Today's Living Hope is dedicated to Tori's father TIM LARRICK
A Conversation with 2021's Miss Arizona Amber Barto and Roger E. Magowitz About Pancreatic Cancer Episode 15 Barto's journey in pageants started when she was 15 years old. She first served as Miss City of Maricopa's Outstanding Teen in 2013 and went on to serve as Miss Arizona's Outstanding Teen in 2014. After competing in the Miss America's Outstanding Teen competition in 2014 and serving as Miss Scottsdale in 2019, Barto aspired to represent the state on an even bigger scale. “Stepping on that stage was a dream come true. Competing for Miss Arizona was something I waited for for about seven years,” Barto said. “When my name was announced as Miss Arizona, it was surreal and just felt like such a full-circle moment to be there and standing on the Miss Arizona stage. It's an experience unlike any other, being given that opportunity.” In addition to winning the Miss Arizona title, she also won the preliminary talent and red-carpet evening wear awards as well as the quality of life award for her social impact initiative, Leadership Through Service, which encourages youth to become involved in community service by bringing awareness to different causes and nonprofits. As part of this initiative, she has helped raise over $300,000 to benefit local charities and has volunteered more than 1,000 hours annually. As Miss Arizona, Barto said she hopes to continue inspiring community service participation, specifically within local youth populations. “I would love to travel the state of Arizona and do a full school tour to talk about the importance of community service,” Barto said. “With younger kids, it's really about instilling that concept of empathy and selflessness while teaching that giving back is something really incredible. I also want to help people find causes that they're really passionate about.” The 23-year-old has lived in Arizona since she was 5 years old, growing up in the city of Ahwatukee. She has been an avid dancer since she was 2 and has won many awards, including an Olympic-recognized gold medal with the Arizona State Dance Team. Barto serves as the communications director for the Phoenix affiliate of the Pancreatic Cancer Action Network, where she coordinates local media coverage and social media and advocates for funding and research initiatives. --- Send in a voice message: https://anchor.fm/seena-magowitz-foundation/message
We all know that October is Breast Cancer Awareness month but did you know November begins Pancreatic Awareness month? Join me today to meet the inspirational leader of Pancreatic Cancer Action NetworkorPanCAN Julie Fleshman and learn about her incredible journey in changing lives.
Paul Sharp returns! Join the guys and Paul as they sit down and discuss Paul's upcoming charity run/row for the Pancreatic Cancer Action Network. Plus, we pick the winners for our giveaway! Enjoy!Website: https://secure.pancan.org/site/TR?px=2254300&fr_id=2262&pg=personalMissionpreppodcast.comInstagram: @paul_sharp_sbg @missionpreppodcastSponsors: Adaptivetactical.com Use code: MP20 Mountainprimal.com Use code MISSIONPREP
In this episode, Holly & Kristin talk with Deborah Shames about: Early career experiences that created the platform for Deborah's commitment to showing up confident and polished. It wasn't an easy road for Deborah either! An amazing story of commitment and courage. Deborah's passion for helping others (and especially women) feel confident, prepared, and competent in their roles as executives, leaders and entrepreneurs. The secrets to being “memorable” when you present. The things women need to let go of to show up as confident, competent and authentic. Key Takeaways When you need to address an audience or present a topic, always know your intention. Right before you present, review your intention for the meeting or presention, not the content. Never write out, read or memorize your content as this comes across as inauthentic Pick only three items that you want to cover in your content as this makes remembering content easier and doesn't overwhelm your audience with too many messages. Deborah Shames, Prior to co-founding Eloqui with David Booth, Deborah was an award-winning film and television director. She founded the only female owned production company in the San Francisco Bay Area-- Focal Point Productions, which she ran for 15 years. Deborah directed luminaries including Wendie Malick, Rita Moreno, Danny Glover, and Angela Lansbury. Deborah coaches female executives on presentation and communication skills. She preps authors, CEO's and executives before media tours, and works with celebrity and on-air talent at major television studios. Deborah is frequently engaged prior to national sales meetings or product launches as a keynote speaker or coach, and for leadership development training. Eloqui trains companies to deliver with style and passion. Their clients include CUNA Mutual, Amgen, Prolacta BioScience, OneAmerica, Northern Trust, Mattel, Samsung Chemical, and Hyundai Hata, as well as law, financial and insurance firms. Deborah enjoys coaching individuals to identify their strengths, utilize their authentic voice and drive business. Eloqui also serves non-profits, especially around fund raising. From the Pancreatic Cancer Action Network, Global GLOW, and the Arthritis Foundation to Ability First, Deborah trains the CEO and senior management teams as well as volunteers. Her latest non-profit client is THORN, founded by Demi Moore and Ashton Kutcher. Demi also calls on Deborah for coaching before her public appearances. Deborah received a “Consultant of the Year” award by the San Fernando Valley Business Journal. When not working, Deborah travels, does photography, hikes in the mountains, and makes jewelry. Deborah and her partner David wrote: Own the Room: Business Presentations that Persuade, Engage, and Get Results that was published by McGraw-Hill and is now it's in third printing. It is considered a business bestseller. And Deborah's latest book is for women professionals: Out Front: How Women can Become Engaging, Memorable and Fearless Speakers and was published by BenBella Books. Connect with Deborah: Email: dshames@eloqui.biz LinkedIn: https://www.linkedin.com/in/deborahshames/ Website: www.outfront.biz Twitter: https://twitter.com/women_outfront Facebook: https://www.facebook.com/womenoutfront Guest Resource Links: Check out Eloqui's Services at: www.eloqui.biz Don't forget to sign up for their amazing weekly newsletter while you're on the website. 17 years and going strong! Books: Out Front: How Women Can Become Engaging, Memorable and Fearless Speakers Out Front: How Women Can Become Engaging, Memorable, and Fearless Speakers: Shames, Deborah: 9781941631676: Amazon.com: Books Own the Room: Business Presentations that Persuade, Engage, and Get Results Own the Room: Business Presentations that Persuade, Engage, and Get Results: Booth, David, Shames, Deborah, Desberg, Peter: 9780071628594: Amazon.com: Books UPLIFTING WOMEN HOSTS Kristin Strunk and Holly Teska Your co-hosts of the UPLIFTING WOMEN PODCAST, Holly Teska & Kristin Strunk, are women who UPLIFT other women at work and in the world. Every other week they bring uplifting women guests to share their personal stories of challenge and triumph to inform and inspire their listeners. The podcast also features guests who have played a significant role in honoring women and their place in the world by serving as promoters, sponsors, and coaches to the many women in their personal and professional lives. Join Holly and Kristin as they hear how their guests navigate the world of career aspirations, life, love, and family. Get advice from successful women who have figured out their own version of "secret sauce" to create the life they love. Holly believes the world needs the best leaders it can build; those who demonstrate integrity, empathy, humility, vision, positivity, and confidence. This type of leader brings out the best in others and delivers outstanding results. Holly feels we need everyone to perform at 100% to making our world a better place. Holly's experience in leadership, executive coaching, and talent development is the foundation of her career. She has helped bright and motivated leaders become the very best versions of themselves. Through direct feedback, reflection, experimentation, and honest conversation, she will push you to excel at what you were called to do. Holly is especially committed to helping women navigate the choppy waters of today's fast-paced workplace and evolving world conditions but works with many different individuals and situations. She welcomes inquiries for leadership and executive coaching and speaking engagements. Kristin's experiences have led her to the simple conclusion that leadership is simple - maybe not always easy, but simple. Her work supporting leaders in finding their voices inspired her to find her own voice in the space of employee experience and leadership development. She often hears the question that isn't being asked and is skilled at facilitating conversations and building relationships. She has helped executives lead organizational transformations involving employee engagement, technology, and the new "Future of Work." Follow her hashtag #responsibleleadership on social media to learn more about simple things leaders can do to build relationships and have a lasting positive impact. Website: www.upliftingwomen.net Connect with Holly: LinkedIn: https://www.linkedin.com/in/hollyteska Twitter: https://twitter.com/HollyTeska Facebook: https://www.facebook.com/holly.teska Instagram: https://instagram.com/HollyTeska Personal Website: www.hollyteska.com Email: holly@upliftingwomen.net Connect with Kristin: LinkedIn: https://www.linkedin.com/in/kristin-strunk Twitter: https://twitter.com/leadadvisor Facebook: https://www.facebook.com/kristin.t.strunk Instagram: https://instagram.com/ktuttlestrunk Personal Website: https://regentleadershipgroup.com/ Email: kristin@upliftingwomen.net
Academy/Golden Globe Award winners Franke Previte & John DeNicola were down to the bottom of their bank accounts in 1987 when their lives changed forever.The Dirty Dancing original soundtrack spent 18 weeks at #1 on the Billboard 200 album sales chart and 230 weeks in the Top 30. As one of the greatest selling soundtracks of all time, the film became an iconic classic almost as soon as it hit the theaters in 1987...33 years later the Dirty Dancing brand is a cultural phenomenon.Knowing the feeling of being hungry, Previte & DeNicola felt since their lives have been musically rewarded they have been donating thousands of dollars to charity. When their Dirty Dancing friend Patrick Swayze passed they contacted Swayze's wife Lisa and decided to donate proceeds from the sale of the "Dancing Dancing: The Original Demos" to the Pancreatic Cancer Action Network in memory of Patrick. "Dirty Dancing: The Original Demos" features the original recordings (with Franke on lead vocals) of "(I've Had The Time Of My Life" + 'Hungry Eyes" . These original versions are what Patrick & Jennifer filmed their Dirty Dancing dance sequences to. When the pandemic invaded our world Franke & John felt it was important to revive a couple of their previous songs from the last century in order to help heal those in need through the power of music.. While on a groundbreaking summit in Russia in 1989 Franke co-wrote "One World" with another American along with two Estonians...originally recorded by Earth Wind & Fire Previte realize how the song fits in today's world of pandemic and social injustice...and hence a new recording was released with all proceeds being donating to several non-profits. DeNicola's new pandemic relevant version of "Hungry Eyes" along with "One World" have been shown recently at several drive-in theaters...including a recent food bank fundraising screening of Dirty Dancing.The Oscar Winning Duo recently amassed High Charted "New" Songs on AC Radio...One World and Hungry Eyes..... Their songs have been raising awareness and funds to support pandemic and social injustice causes.https://www.oneworldoursong.com/https://www.taylorsimonking.com/https://www.omadrecords.com/
It's all come down to this! Kyle Demetrius (Sharks), Laura Saba (Canadiens), and Trey Matthews (Devils) have earned the right to play in this "Hockey Jeopardy!" Tournament of Champions. JD hosts this special event all while raising money for the Pancreatic Cancer Action Network in honor of Alex Trebek. The answers are a little tougher, a wacky category is FINALLY brought out, and a VERY dramatic ending makes this one a "can't miss" episode. Learn more about your ad choices. Visit podcastchoices.com/adchoices
You don't want to miss this conversation with the ultimate Purple Warriors, Dr. Lynn Matrisian(CSO) and President and CEO Julie Fleshman of the Pancreatic Cancer Action Network, and discussed everything from our collective concerns about clinical trial accrual to some exciting things happening in the field right now...
© 2020-2025 Ivy Podcast Discovery LLC
